Coronary disease & ACSRandomised controlled trial
Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial
- Randomised controlled trial
- double-blind
- dose-finding
- placebo-controlled
Authors' conclusion
In summary, despite favorable effects on sLOX-1 and IL-6, a LOX-1 inhibitor did not reduce noncalcified coronary plaque volume in patients with residual inflammation after acute MI.
Study context
- Population
- Patients 30–365 days after myocardial infarction (MI) with residual inflammation (hs-CRP ≥ 1 mg l-1)75 women · 348 men
- Participants
- 423 patients
- Comparison
- MEDI6570 50, 150 or 400 mg vs placebo
- Primary endpoint
- Change in noncalcified plaque volume in the most diseased coronary segment (NCPVMD) by CT angiography
Primary result
As reported in the abstract
Change in NCPVMD
- Not significantly different between placebo and MEDI6570 at any dose
Secondary outcomes
Free soluble LOX-1 reduction from baseline (exploratory)
| Outcome | Placebo | 50 mg | 150 mg | 400 mg |
|---|---|---|---|---|
| IL-6 decrease (exploratory) | 2.9% | −3.0% | 18.9% | 21.5% |
- Free soluble LOX-1 reduction from baseline (exploratory): all placebo-adjusted comparisons P < 0.001
- IL-6 decrease (exploratory): placebo-adjusted reductions only at 150 mg and 400 mg (P < 0.05)
Global NCPV and low-attenuation plaque volume
- Not different between placebo and MEDI6570 at any dose
- P > 0.05
- all placebo-adjusted comparisons
Safety
Serious adverse events
- Well tolerated; SAE rates similar with MEDI6570 and placebo
Original publication
Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial. Nat Med. Published 25 September 2025. doi:10.1038/s41591-025-03951-w
Summarised from the published abstract; every number is checked against it